Core Viewpoint - Genting New Year (01952) saw a significant increase of over 4% in its stock price, attributed to the announcement of two strategic cooperation agreements with Haisen Biopharmaceutical Co., Ltd. [1] Group 1: Strategic Cooperation Agreements - Genting New Year’s wholly-owned subsidiary, Genting New Year Pharmaceutical Technology Co., Ltd., signed two strategic cooperation agreements with Haisen Biopharmaceutical [1] - Under the commercialization service agreement, Genting New Year Pharmaceutical Technology will leverage its existing sales and marketing system to provide commercialization services for six mature products from Haisen Biopharmaceutical, focusing on critical care, cardiovascular, and metabolic fields [1] Group 2: Licensing Agreement - The licensing agreement grants Genting New Year Pharmaceutical Technology exclusive rights to conduct further clinical development, registration, and commercialization of Lerodalcibep in Greater China, enhancing its late-stage pipeline [1] - Genting New Year Pharmaceutical Technology will make an initial payment of approximately 205 million yuan, with potential development and regulatory milestone payments not exceeding 212 million yuan, and potential sales milestone payments not exceeding 1.977 billion yuan, along with royalties based on net sales [1]